 PLANO, Texas--BUSINESS WIRE--Reata Pharmaceuticals, Inc. Nasdaq: RETA Reata, the Company, our, us, or we, a clinical-stage biopharmaceutical company, today announced that it will report financial results for the second quarter ended June 30, 2022, and provide an update on the Companys business operations and clinical development programs on August 8, 2022, before the U.S. financial markets open. Conference Call Information Reatas management will host a conference call on Augus 